© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 18, 1396-1406,
September 18, 2002
© 2002 Oxford University Press
ARTICLE |
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
Affiliations of authors: J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann-Zogg, R. E. Buller (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center), B. DeYoung (Department of Pathology), University of Iowa Hospitals and Clinics, Iowa City.
Corresponding author: Richard E. Buller, M.D., Ph.D., University of Iowa Hospitals and Clinics, 200 Hawkins Dr., Iowa City, IA 52242 (e-mail: richard-buller{at}uiowa.edu).
Background: Although BRCA1 and BRCA2 play important roles in hereditary ovarian cancers, the extent of their role in sporadic ovarian cancers and their mechanisms of inactivation are not yet well understood. Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression. Methods: The tumors of 92 unrelated women with "ovarian" cancer (i.e., ovarian, peritoneal, or fallopian tube cancer) were screened for BRCA2 null mutations using a protein truncation test. Methylation-specific polymerase chain reaction (PCR) was used to examine the BRCA2 promoter for hypermethylation in tumors that did not express BRCA2 mRNA. All statistical tests were two-sided. Results: Nine tumors had a germline (n = 5) or somatic (n = 4) BRCA2 mutation; each was associated with loss of heterozygosity. All of the somatic (1445delC, E880X, 4286del8, and 5783delT) and one of the germline (5984ins4) mutations were unique to this study. One tumor had somatic mutations in both BRCA1 and BRCA2. Two tumors are, to our knowledge, the first cases of germline BRCA2-associated peritoneal cancer. Twelve additional tumors lacked detectable BRCA2 mRNA, but the BRCA2 promoter was hypermethylated in only one of them, suggesting that other mechanisms effect transcriptional silencing of BRCA2. Tumors lacking BRCA1 mRNA were more likely to lack BRCA2 mRNA than tumors expressing BRCA1 mRNA (P<.001). Overall, 82% (95% confidence interval [CI] = 74% to 90%) of the tumors contained alterations in BRCA1, BRCA2, or both genes. Of 41 informative tumors with some alteration in BRCA2, 36 also had an alteration in BRCA1. The frequency, but not the mechanism, of BRCA1 or BRCA2 dysfunction in ovarian cancer was independent of family history. Conclusions: Multiple mechanisms cause nearly universal dysfunction of BRCA1 and/or BRCA2 in hereditary and sporadic ovarian carcinoma. Ovarian cancers with BRCA2 dysfunction often have simultaneous BRCA1 dysfunction.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Willems, S.-J. Dawson, H. Samaratunga, A. De Luca, Y. C. Antill, J. L. Hopper, H. J. Thorne, and and kConFab Investigators Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation Clin. Cancer Res., May 15, 2008; 14(10): 2953 - 2961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, J. Weaver, B. A. Bove, L. A. Vanderveer, S. C. Weil, A. Miron, M. B. Daly, and A. K. Godwin Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk Hum. Mol. Genet., May 1, 2008; 17(9): 1336 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Swisher, W. Sakai, B. Y. Karlan, K. Wurz, N. Urban, and T. Taniguchi Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance Cancer Res., April 15, 2008; 68(8): 2581 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W G McCluggage My approach to and thoughts on the typing of ovarian carcinomas J. Clin. Pathol., February 1, 2008; 61(2): 152 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-N. Lee, R.-C. Tseng, H.-S. Hsu, J.-Y. Chen, C. Tzao, W. L. Ho, and Y.-C. Wang Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non-Small Cell Lung Cancer Clin. Cancer Res., February 1, 2007; 13(3): 832 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Kennedy and A. D. D'Andrea DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Yarden and M. Z. Papa BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol. Cancer Ther., June 1, 2006; 5(6): 1396 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin The Role of BRCA1 in the Cellular Response to Chemotherapy J Natl Cancer Inst, November 17, 2004; 96(22): 1659 - 1668. [Abstract] [Full Text] [PDF]
|
|